Clinilabs, a US-based contract research organisation (CRO) focused on early-phase and specialty clinical drug development services, has announced a collaborative agreement with the Epilepsy Study Consortium, offering a “seamless approach” to the development of anti-epileptic drugs (AEDs).

Under the agreement, the new partners will provide integrated consultation and clinical development services to pharmaceutical and biotechnology companies running Phase I and II trials of AEDs.

The Epilepsy Study Consortium is a group of scientific investigators from academic medical centres dedicated to accelerating the development of new and improved therapies for epilepsy. Dr Jacqueline French, the Consortium’s president, is joining Clinilabs’ Scientific Advisory Board.

Clinilabs was founded by president and chief executive officer Dr Gary Zammit in 2001 and operates out of a custom-built, 32,000 sq. ft. facility in mid-town Manhattan, New York.